[Incidence of rigor during treatment with flupentixol decanoate in comparison to risperidone].

STUDY OBJECTIVE

We investigated as to whether dosedependent extrapyramidal tolerance of Flupentixol decanoate is inferior to that of Risperidone.

METHOD

143 Risperidone and 177 Flupentixol decanoate treated patients were consecutively entered into this non - randomized open study and assessed with the Simpson-Angus-Scale regarding presence of rigor. Treatment comparisons of rigor frequency was done by Kaplan-Meier analysis.

RESULTS

The risk of rigor increased with dose on both treatments. EPMS-risk was not increased under treatment with Flupentixol decanoate (mean dose 35.06 +/- 19.7 mg/2 weeks) compared to Risperidone (mean daily dose: 5.2 +/- 2.5 mg/kg) when comparable weight standardized Haloperidol equivalence doses (WHE) were used.

CONCLUSION

This study offers limited evidence for methodological reasons. Yet, results do not support the view that EPS are more frequent on Flupentixol decanoate than on Risperidone when doses are comparable.